Navigation Links
Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Date:2/14/2013

udy enrolled prior to the fourth quarter of 2013.
  • Phase III study of ibrutinib versus chlorambucil in frontline newly diagnosed elderly CLL/SLL patients, RESONATE™ -2.  This trial is a randomized, multicenter, open-label study of ibrutinib as a monotherapy versus chlorambucil in patients 65 years or older with treatment naïve CLL/SLL. The study design was granted a Special Protocol Assessment (SPA), designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival when compared to chlorambucil. This global study is open and Pharmacyclics plans to enroll 272 patients worldwide. The Company anticipates enrollment for this study will take approximately 18 months to complete. 
  • Phase III study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory CLL/SLL, HELIOS (CLL3001). This trial is a randomized, multi-center, double blinded, placebo controlled trial of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory CLL/SLL patients who received at least one line of prior systemic therapy. The primary endpoint of the study is to demonstrate a clinically significant improvement in progression-free survival when compared to bendamustine and rituximab. This global study, conducted by Janssen, is open and Janssen plans to enroll 580 patients worldwide.
  • Phase II study, RESONATE™ -17p, which is a single-arm, open-label, multi-center trial using ibrutinib as a monotherapy in patients who have deletion 17p and who did not respond to or relapsed after at least one prior treatment with chemo immunotherapy (a high unmet need population). The primary endpoint of the study will be overall response rate. This global study is open and Pharmacyclics plans to enroll 111 patients worldwide. The Company anticipates enrollment for this study will take approximately 12 months to complete.
  • Phase III study of ibrutinib ver
    '/>"/>

  • SOURCE Pharmacyclics, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    2. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    3. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    4. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    5. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    6. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    7. Pharmasset Reports Fiscal Year End 2011 Financial Results
    8. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    9. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    10. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
    11. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014 /PRNewswire/ ... will be a 177-key, 4-star boutique hotel in the heart ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... the first hotel within ATLAS , The ... mixture of standard rooms and suites, a sleek restaurant and bar, ...
    (Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
    (Date:7/25/2014)... 25, 2014 Research and Markets ... Metabolomics Market 2014-2018" report to their offering. ... Metabolomics or Metabonomics is the scientific study ... a new experimental technique that is being widely ... Metabolites are small molecules that are present in ...
    (Date:7/25/2014)... California (PRWEB) July 25, 2014 Lawrence ... named to Thomson Reuters list of " The World's ... are part of the 3,000 researchers who were identified ... to recognize those who published the highest-impact work (2002-2012 ... research papers on combustion modeling . , "This ...
    Breaking Biology Technology:Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4
    ... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will Webcast ... 2008 on Tuesday, October 21, 2008 at 5:00 p.m. ... Executive,Officer, will lead the call. On the same date ... of 2008., The call will be Webcast live ...
    ... Data Demonstrates 30% Reduction in Composite Events When Using Routine ... FFR Guidance in ... VOLC ) today announced the launch of the PrimeWire(TM) Pressure,Guidewire, ... s5 and,s5i imaging consoles in the U.S. The PrimeWire is ...
    ... Colo., Oct. 15 Bolder BioTechnology, Inc.,announced today ... Phase II Continuing,Renewal Small Business Innovation Research (SBIR) ... the National,Institute of Neurological Disorders and Stroke (NINDS) ... the entire grant award is contingent,upon the achievement ...
    Cached Biology Technology:Amylin Pharmaceuticals to Webcast Third Quarter Results 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 2Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 3Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 4Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and s5-FFR Option for Existing Fleet of s5 IVUS Consoles 5Bolder BioTechnology Receives $1.6 million NIH Grant to Continue Development of Multiple Sclerosis Drug 2
    (Date:7/28/2014)... Earth that are high priorities for conservation in the ... as it has the lowest fraction of its land ... ,refugia, areas of biological diversity that support many ... times of great environmental change. The refugia that do ... , The biggest refugia are in the Amazon, ...
    (Date:7/28/2014)... hunter, but the target of his work consists of ... special methods and instruments. Benjamin Hause, an assistant research ... Kansas State University, recently published an article about one ... important find in the United States. , "We had ... it was," Hause said. "We used next-generation sequencing to ...
    (Date:7/28/2014)... found that 73 percent of adult survivors of childhood ... syndrome and related health problems by failing to follow ... issue of the journal Cancer . , Almost ... cancer in the study had metabolic syndrome, an umbrella ... abdominal obesity, elevated triglyceride and other abnormalities that often ...
    Breaking Biology News(10 mins):Study finds Europe's habitat and wildlife is vulnerable to climate change 2Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
    ... lipid synthesis in the liver, UC Irvine endocrinologists have revealed ... With this finding, Dr. Ellis Levin and colleagues believe ... appear in the May 21 issue of the journal ... field for 50 years has been that only receptors located ...
    ... health, development, and academic success of children, schools should ... have opportunities to engage in at least 60 minutes ... a new report from the Institute of Medicine. ... children meet this evidence-based guideline for promoting better health ...
    ... (May 23, 2013) A new report from the ... pupils engage in at least 60 minutes of vigorous or ... than half of American youth meet current evidence-based guidelines of ... activity daily, according to the report, which was released today. ...
    Cached Biology News:UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
    DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
    ...
    ... PGE1-d4 contains 4 deuterium atoms at ... It is intended for use as an ... by GC- or LC-mass spectrometry. PGE1 is ... (DGLA), but it is virtually undetectable in ...
    Assay Diluent Trial Pack, 4 x 100 mL...
    Biology Products: